The global market for Adult Vaccines was valued at US$16.6 Billion in 2024 and is projected to reach US$22.5 Billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Adult Vaccines market.
Growing recognition of vaccine-preventable disease burdens among adults, particularly the elderly and immunocompromised, is reshaping immunization policies and healthcare delivery models. Governments, insurers, and employers are increasingly integrating adult vaccines into preventive care frameworks, emphasizing the importance of lifelong protection in enhancing public health resilience and system sustainability.
On the delivery side, expansion of pharmacy-based vaccination, mobile clinics, and workplace immunization programs is improving accessibility and uptake. Digital health tools - such as vaccine reminders, mobile scheduling, and immunization records - are enhancing adherence and reducing missed opportunities. These models are increasingly supported by public-private partnerships aimed at closing coverage gaps and strengthening immunization infrastructure for adults.
North America leads in vaccine uptake due to mature reimbursement frameworks, strong retail pharmacy participation, and government-supported vaccination programs. Europe follows with robust public health infrastructure and aging demographics. Asia-Pacific is experiencing rapid growth, driven by urbanization, improved healthcare access, and post-pandemic immunization awareness. Meanwhile, Latin America and parts of Africa are expanding adult vaccine access through WHO-backed initiatives and regional disease control programs.
Health equity is becoming a priority, with stakeholders targeting education, cultural competency, and financial barriers to improve vaccine access for marginalized groups. Behavioral science is also informing strategies to address vaccine hesitancy, leveraging trusted community partnerships and tailored messaging. These efforts are essential in maximizing the reach and impact of adult immunization programs in diverse global contexts.
Looking forward, market momentum will depend on how effectively stakeholders align innovation, equity, and education in scaling adult immunization worldwide. As healthcare systems pivot toward prevention-first models, could adult vaccines become the most strategic lever for sustainable, population-wide disease control?
Segments: Technology (Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate, Other Technologies); Vaccine Type (Monovalent Vaccine, Multivalent Vaccine); End-Use (Private Healthcare Firms, Government Hospitals).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Adult Vaccines Market - Key Trends & Drivers Summarized
Why Are Adult Vaccines Becoming Central to Lifelong Immunization Strategies and Public Health Resilience?
Adult vaccines are increasingly recognized as critical tools in disease prevention, population health management, and healthcare cost containment. While traditionally associated with childhood immunization, vaccines for adults now target a wide range of infectious diseases - including influenza, pneumococcal disease, shingles, hepatitis, HPV, and COVID-19 - as well as travel-related and occupational exposures. As global populations age and chronic conditions become more prevalent, adult immunization is emerging as a frontline strategy to reduce morbidity, hospitalization, and productivity loss.Growing recognition of vaccine-preventable disease burdens among adults, particularly the elderly and immunocompromised, is reshaping immunization policies and healthcare delivery models. Governments, insurers, and employers are increasingly integrating adult vaccines into preventive care frameworks, emphasizing the importance of lifelong protection in enhancing public health resilience and system sustainability.
How Are Vaccine Technologies and Delivery Models Evolving to Meet Adult Immunization Needs?
Advancements in recombinant technologies, conjugate formulations, and mRNA platforms are driving next-generation adult vaccine development. These innovations offer improved immunogenicity, longer-lasting protection, and broader strain coverage, enabling more effective prevention of respiratory, sexually transmitted, and vector-borne infections. Adjuvant systems and age-targeted formulations are being optimized to overcome immunosenescence and improve efficacy in older populations.On the delivery side, expansion of pharmacy-based vaccination, mobile clinics, and workplace immunization programs is improving accessibility and uptake. Digital health tools - such as vaccine reminders, mobile scheduling, and immunization records - are enhancing adherence and reducing missed opportunities. These models are increasingly supported by public-private partnerships aimed at closing coverage gaps and strengthening immunization infrastructure for adults.
Which Disease Areas and Regional Markets Are Driving Growth in the Adult Vaccines Segment?
Respiratory diseases, including influenza, COVID-19, and pneumococcal infections, remain the highest-volume adult vaccine categories, followed by HPV, shingles, and hepatitis. Demand is particularly strong for booster doses, seasonal immunizations, and vaccines for travel-related risks. The introduction of adult-targeted combination vaccines and expanded indications for HPV and shingles immunization are further diversifying demand across age groups and risk profiles.North America leads in vaccine uptake due to mature reimbursement frameworks, strong retail pharmacy participation, and government-supported vaccination programs. Europe follows with robust public health infrastructure and aging demographics. Asia-Pacific is experiencing rapid growth, driven by urbanization, improved healthcare access, and post-pandemic immunization awareness. Meanwhile, Latin America and parts of Africa are expanding adult vaccine access through WHO-backed initiatives and regional disease control programs.
How Are Policy Mandates, Health Equity Goals, and Behavioral Factors Influencing Market Development?
National immunization programs and CDC/WHO guidelines are expanding adult vaccine recommendations, particularly for older adults, pregnant women, and individuals with chronic illnesses. Pandemic-era investments in cold chain capacity, surveillance, and data infrastructure are being leveraged to support broader adult immunization campaigns. However, disparities in access, awareness, and vaccine confidence continue to impact uptake, particularly in underserved populations.Health equity is becoming a priority, with stakeholders targeting education, cultural competency, and financial barriers to improve vaccine access for marginalized groups. Behavioral science is also informing strategies to address vaccine hesitancy, leveraging trusted community partnerships and tailored messaging. These efforts are essential in maximizing the reach and impact of adult immunization programs in diverse global contexts.
What Are the Factors Driving Growth in the Adult Vaccines Market?
The adult vaccines market is expanding rapidly as aging populations, emerging infectious threats, and health system reforms elevate the importance of preventive care. Key growth drivers include technological advances in vaccine platforms, increased investment in immunization infrastructure, broader policy mandates, and growing awareness of adult disease risks. Industry innovation is focused on developing multi-pathogen vaccines, single-dose regimens, and scalable distribution models that enhance both convenience and protection.Looking forward, market momentum will depend on how effectively stakeholders align innovation, equity, and education in scaling adult immunization worldwide. As healthcare systems pivot toward prevention-first models, could adult vaccines become the most strategic lever for sustainable, population-wide disease control?
Report Scope
The report analyzes the Adult Vaccines market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Technology (Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate, Other Technologies); Vaccine Type (Monovalent Vaccine, Multivalent Vaccine); End-Use (Private Healthcare Firms, Government Hospitals).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Live Attenuated Vaccines segment, which is expected to reach US$6.9 Billion by 2030 with a CAGR of a 6.5%. The Inactivated Vaccines segment is also set to grow at 5.9% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $4.5 Billion in 2024, and China, forecasted to grow at an impressive 9.6% CAGR to reach $4.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Adult Vaccines Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Adult Vaccines Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Adult Vaccines Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Altimmune, Inc., AstraZeneca plc, Bavarian Nordic A/S, Bharat Biotech International Ltd., Biological E. Limited and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 41 companies featured in this Adult Vaccines market report include:
- Altimmune, Inc.
- AstraZeneca plc
- Bavarian Nordic A/S
- Bharat Biotech International Ltd.
- Biological E. Limited
- CanSino Biologics Inc.
- CSL Limited
- Daiichi Sankyo Co., Ltd.
- Emergent BioSolutions Inc.
- GeneOne Life Science Inc.
- GlaxoSmithKline plc
- ImmunityBio, Inc.
- Inovio Pharmaceuticals, Inc.
- Johnson & Johnson
- Medigen Vaccine Biologics Corp.
- Meiji Seika Pharma Co., Ltd.
- Merck & Co., Inc.
- Moderna, Inc.
- Novavax, Inc.
- Pfizer Inc.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Altimmune, Inc.
- AstraZeneca plc
- Bavarian Nordic A/S
- Bharat Biotech International Ltd.
- Biological E. Limited
- CanSino Biologics Inc.
- CSL Limited
- Daiichi Sankyo Co., Ltd.
- Emergent BioSolutions Inc.
- GeneOne Life Science Inc.
- GlaxoSmithKline plc
- ImmunityBio, Inc.
- Inovio Pharmaceuticals, Inc.
- Johnson & Johnson
- Medigen Vaccine Biologics Corp.
- Meiji Seika Pharma Co., Ltd.
- Merck & Co., Inc.
- Moderna, Inc.
- Novavax, Inc.
- Pfizer Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 377 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 16.6 Billion |
| Forecasted Market Value ( USD | $ 22.5 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
